Liu, Lianxin |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
SHR-8068-301, NCT06618664: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 560 | RoW | SHR-8068, Adebrelimab, Bevacizumab, Sintilimab | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Hepatocellular Carcinoma | 03/26 | 12/30 | | |
NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 72 | RoW | HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA® | Taizhou Hanzhong biomedical co. LTD | Hepatocellular Carcinoma | 04/22 | 10/22 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT06498622: Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab |
|
|
| Recruiting | 2 | 45 | RoW | Donafenib + Envafolimab | Anhui Provincial Hospital | Hepatocellular Carcinoma | 05/27 | 05/27 | | |
NCT06673498: Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery |
|
|
| Recruiting | 2 | 60 | RoW | Lusutrombopag combined with recombinant human thrombopoietin | Anhui Provincial Hospital | Thrombocytopenia | 11/25 | 11/25 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
BGB-Sitra-2001-IIT, NCT05407519: A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab + Sitravatinib | Anhui Provincial Hospital, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital | Hepatocellular Carcinoma | 06/26 | 06/26 | | |
NCT05444088: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 129 | RoW | Adebrelimab, Bevacizumab, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Hepatocellular Carcinoma | 06/26 | 06/26 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT06296095: To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis |
|
|
| Enrolling by invitation | 1 | 9 | RoW | Cell therapy | Anhui Provincial Hospital | Cirrhosis, Liver | 10/24 | 12/24 | | |
| Recruiting | 1 | 112 | RoW | TQB3006 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 03/25 | 08/26 | | |
NCT06671275: A Clinical Study to Evaluate CUD005 Injection in Patients with Liver Cirrhosis |
|
|
| Enrolling by invitation | 1 | 9 | RoW | Cell therapy | Anhui Provincial Hospital | Cirrhosis Liver | 10/25 | 07/26 | | |
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations |
|
|
| Active, not recruiting | 1 | 54 | Europe, US, RoW | KIN-3248 | Kinnate Biopharma | Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma | 06/26 | 09/26 | | |
| Recruiting | N/A | 10000 | RoW | | Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital | Gallbladder Neoplasms | 12/22 | 12/25 | | |
NCT05457374: A Clinical Study of Portal Vein Embolization and Liver Venous Deprivation |
|
|
| Recruiting | N/A | 10 | RoW | PVE, LVD | Anhui Provincial Hospital | Liver Venous Deprivation | 03/24 | 03/25 | | |
NCT06611345: A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers |
|
|
| Recruiting | N/A | 60 | RoW | Tumor Treating Fields, Durvalumab, Gemcitabine, Cisplatin | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, AstraZeneca | Biliary Tract Cancers (BTC) | 10/26 | 03/27 | | |
NCT06777485: China Liver Cancer Clinical Registry Cohort Database |
|
|
| Recruiting | N/A | 10000 | RoW | Procedure/Surgery treatment, Anti-Tumor Drugs | Anhui Provincial Hospital | Liver Cancer | 01/35 | 01/35 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Active, not recruiting | N/A | 501 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |